KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Intangibles (2021 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Intangibles for 6 consecutive years, with $1.3 billion as the latest value for Q1 2026.

  • For Q1 2026, Intangibles rose 10.27% year-over-year to $1.3 billion; the TTM value through Mar 2026 reached $1.3 billion, up 10.27%, while the annual FY2025 figure was $1.3 billion, 9.47% up from the prior year.
  • Intangibles hit $1.3 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Across five years, Intangibles topped out at $1.4 billion in Q3 2025 and bottomed at $155.0 million in Q2 2025.
  • Average Intangibles over 5 years is $1.0 billion, with a median of $1.1 billion recorded in 2024.
  • Year-over-year, Intangibles surged 13564.18% in 2022 and then tumbled 85.94% in 2025.
  • Regeneron Pharmaceuticals' Intangibles stood at $915.5 million in 2022, then grew by 13.45% to $1.0 billion in 2023, then rose by 10.59% to $1.1 billion in 2024, then grew by 9.47% to $1.3 billion in 2025, then grew by 2.35% to $1.3 billion in 2026.
  • According to Business Quant data, Intangibles over the past three periods came in at $1.3 billion, $1.3 billion, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.